Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

The Lancet Oncology

Volumn 13, Issue 10, 2012, Pages

  Schneider, Bryan P ^a   Shen, Fei ^a   Miller, Kathy D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN PLUS PACLITAXEL; CYCLOPHOSPHAMIDE; DOCETAXEL; ERLOTINIB PLUS GEMCITABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; PACLITAXEL; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANEMIA; ANTIANGIOGENIC THERAPY; BREAST CANCER; COLON CANCER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKOPENIA; LOW DRUG DOSE; LUNG CANCER; MUCOSA INFLAMMATION; ONCOGENE; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; VEGFA GENE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; HUMANS; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84866849940     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70275-9     Document Type: Review

References (55)

1. Folkman J Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
2. Kerbel RS Tumor angiogenesis. N Engl J Med 2008, 358:2039-2049.
3. Schneider BP, Sledge GW Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners?. J Clin Oncol 2011, 29:2444-2447.
4. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
5. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
6. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29:1252-1260.
7. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
8. Kerbel RS A cancer therapy resistant to resistance. Nature 1997, 390:335-336.
9. Moreira IS, Fernandes PA, Ramos MJ Vascular endothelial growth factor (VEGF) inhibition-a critical review. Anticancer Agents Med Chem 2007, 7:223-245.
10. Malhotra B, Evans T, Weiss J, et al. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience. Clin Lung Cancer 2010, 11:192-197.
11. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
12. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009, 20:807-815.
13. Cabebe E, Wakelee H Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 2007, 8:15-27.
14. Choueiri TK Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs 2008, 9:658-671.
15. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008, 26:3743-3748.
16. Shepard DR, Garcia JA Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther 2009, 9:795-805.
17. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009, 6:327-338.
18. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006, 24:217-227.
19. Jubb AM, Miller KD, Rugo HS, et al. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res 2011, 17:372-381.
20. Gianni L, Romieu G, Lichinitser M, et al. First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Cancer Res 2011, 71(suppl 24):S4-S8.
21. Radovich M, Hancock BA, Kassem N, Mi D, Skaar TC, Schneider BP Resequencing of the vascular endothelial growth factor promoter reveals haplotype structure and functional diversity. Angiogenesis 2010, 13:211-218.
22. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672-4678.
23. Miles DW, De Haas SL, Romieu G, et al. Polymorphism analysis in the AVADO randomised phase III trial of first-line bevacizumab (BEV) combined with docetaxel in HER2-negative metastatic breast cancer (mBC). Eur J Cancer 2011, 47(suppl 1):204. (abstr 1423).
24. Pectasides DG, Xanthakis I, Makatsoris T, et al. Irinotecan/capecitabine (XELIRI) plus bevacizumab versus irinotecan/fluorouracil/leucovorin (FOLFIRI) plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a randomized phase III trial of the Hellenic Cooperative Oncology Group (HeCOG). Proc Am Soc Clin Oncol 2010, 28(suppl). abstr 3541.
25. Koutras AK, Antonacopoulou AG, Eleftheraki AG, et al. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J 2011, published online Aug 16. 10.1038/tpj.2011.37.
26. Formica V, Palmirotta R, Del Monte G, et al. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis 2011, 26:143-151.
27. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
28. Zhang W, Dahlberg SE, Yang D, et al. Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: subset pharmacogenetic analysis of ECOG 4599. Proc Am Soc Clin Oncol 2009, 27(suppl). abstr 8032.
29. Schultheis AM, Lurje G, Rhodes KE, et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 2008, 14:7554-7563.
30. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009, 27:2231-2237.
31. Lambrechts D, Claes B, Delmar P, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data for the AViTA and AVOREN randomised trials. Lancet Oncol 2012, 13:724-733.
32. Hutson TE, Davis ID, Machiels J-PH, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010, 28:475-480.
33. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
34. Xu C-F, Bing NX, Ball HA, et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011, 29:2557-2564.
35. Garcia-Donas J, Esteban E, Leandro-García LJ, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011, 12:1143-1150.
36. van der Veldt AAM, Eechoute K, Gelderblom H, et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2011, 17:620-629.
37. Kim JJ, Vaziri SA, Rini BI, et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2011, 118:1946-1954.
38. Schiller JH, Lee JW, Hanna NH, Traynor AM, Carbone DP A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. Proc Am Soc Clin Oncol 2008, 26(suppl). abstr 8014.
39. Zhang W, Lee J, Schiller JH, Carbone DP, Chung CH, Lenz H Use of germline polymorphisms in VEGF to predict tumor response and progression-free survival in non-small cell lung cancer (NSCLC) patients treated with sorafenib: subset pharmacogenetic analysis of Eastern Cooperative Oncology Group (ECOG) trial E2501. Proc Am Soc Clin Oncol 2010, 28(suppl). abstr 7607.
40. Anderson S, Cardenes H, Akisik F, et al. Phase I study of sorafenib (S) with gemcitabine (G)-based radiotherapy (G-RT) in patients (pts) with locally advanced unresectable pancreatic adenocarcinoma (LAUPC). Proc Am Soc Clin Oncol 2010, 28(suppl). abstr 4139.
41. Cella D, Escudier B, Rini BI, et al. Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 4504.
42. Escudier B, Loomis AK, Kaprin A, et al. Association of single nucleotide polymorphisms in VEGF pathway genes with progression-free survival and blood pressure in metastatic renal cell carcinoma in phase 3 AXIS trial of axitinib versus sorafenib (AXIS trial). Eur J Cancer 2011, 47(suppl 1). abstr 7103.
43. Schneider BP, Radovich M, Miller KD The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res 2009, 15:5297-5302.
44. Ebos JML, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acacd Sci 2007, 104:17069-17074.
45. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
46. Osterlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, Bono P Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 2011, 104:599-604.
47. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011, 103:763-773.
48. Jain L, Sissung TM, Danesi R, et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010, 29:95.
49. Hurwitz H, Douglas PS, Middleton JP, et al. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). Proc Am Soc Clin Oncol 2010, 28(suppl). abstr 3039.
50. van Erp NP, Eechoute K, van der Veldt AA, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009, 27:4406-4412.
51. Ashworth A, Lord CJ, Reis-Filho JS Genetic interactions in cancer progression and treatment. Cell 2011, 145:30-38.
52. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 2006, 100:229-235.
53. Simon RM, Paik S, Hayes DF Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009, 101:1446-1452.
54. McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990, 82:1006-1015.
55. Schneider BP, Li L, Miller K, et al. Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 1000.